Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
OPKO Health Inc
OPK
Healthcare
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its...
pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:OPK)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(61)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Mar 31, 2024 9:05pm
BUY BUY BUY BUY BUY
I starting the day with this ... high hopes sings frankie boy
(82)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 04, 2023 1:15am
Opko Health (OPK) Q2 2023 Earnings Call Transcript
BREAKING NEWS: $OPK Opko Health (OPK) Q2 2023 Earnings Call Transcript2023-08-04 01:00:22 ET Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q2 2023 Earnings Call Aug 03, 2023 , 4:30
...more
C.RVV Announces Type C Meeting Request Granted by FDA for Clinical Study
posted Apr 24, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
Currently, the Company is exploring the use of Bucillamine as a potential treatment for long COVID. The Company is advancing the clinical development of Bucillamine by leveraging the published research and data from its previous Phase 3 clinical trial (the “Study”) and is finalizing the regulatory and clinical package that includes a proposed clinical study for long COVID to present to the FDA ...read more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 13, 2023 3:38am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Jul 15, 2022 9:16pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Jun 03, 2022 4:56am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Jun 02, 2022 12:12am
FSD Pharma Files Investigational New Drug Application “IND”
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on May 11, 2022 1:21am
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 30, 2022 3:04am
Lucid-MS for Multiple Sclerosis Treatment
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 22, 2022 12:30am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 16, 2022 3:32am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 09, 2022 1:59am
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)
...more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 07, 2022 12:06pm
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Apr 06, 2022 1:35am
iMining: First Hospital Foundation in Decentraland Metaverse
iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies
...more
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Feb 19, 2022 1:30am
FSD Pharma; Recapping 2021 and What to Look Forward in 2022
(0)
•••
Irene89
X
View Profile
View Bullboard History
Post by
Irene89
on Feb 04, 2022 10:36am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study
Discover a Green Resources Stock Scoring Record Quarterly Growth
Stage Set for Creation of a Leading Intermediate Gold Producer